NEW YORK (GenomeWeb) – T2 Biosystems said after the close of the market yesterday that it has priced its previously announced public offering of 3.5 million shares of common stock at $9.75 a share, giving the sale a value of $34.1 million before costs.
The company has also granted the underwriters of the offering a 30-day option to buy up to 525,000 additional shares at the offering price, minus the underwriting discount. Goldman Sachs is acting as the book-running manager for the offering. Additional underwriters include Leerink Partners, Canaccord Genuity, and Cantor Fitzgerald.
During early morning trading on the Nasdaq, shares of T2 were down $.65 at $9.41.
In September, T2 filed with the US Securities and Exchange Commission to sell up to $100 million of its common stock.